SAN MATEO, CA, USA I January 29, 2025 I Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting ...

Vincerx’s pipeline consists of a next-generation ADC, VIP943, currently in Phase 1; a small molecule drug conjugate, VIP236, which has completed its Phase 1 study; a CDK9 inhibitor, enitociclib, which ...

Novel β-lactamase inhibitors, such as NXL104, BLI-489 and BAL30376, and β-lactam/β-lactamase inhibitor combinations also offer promise. Nontraditional approaches, such as efflux pump inhibitors ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Alsfouk et al. (Alsfouk et al., 2024) employed a computer-assisted design strategy to identify potential CDK9 and CYP3A4 inhibitors by using a predictive QSAR model and in silico synthesis. Molecular ...

Colonial Pipeline said it has completed repairs to a major fuel line that runs through Georgia and returned it to service Friday, four days after a “potential gasoline release” was reported in ...

NDA accepted for review Zynquista (Lexicon Pharmaceuticals) Dual sodium-glucose co-transporter types 1 and 2 inhibitor As an adjunct to insulin therapy for glycemic control in adults with type 1 ...

Clinical Pipeline Progress The cornerstone of Revolution Medicines' value proposition lies in its clinical pipeline, particularly its RAS inhibitors. Two key compounds have been drawing attention ...

Recent developments have centered around the company’s RAS inhibitor pipeline, which has been receiving positive attention from the scientific and investment communities. Revolution Medicines is ...

Recent developments have centered around the company's RAS inhibitor pipeline, which has been receiving positive attention from the scientific and investment communities. Revolution Medicines is ...